The FDA is proposing the removal of phenylephrine, a popular nasal decongestant, in oral form from over-the-counter use. Here ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Financially stable C4 Therapeutics (CCCC) is worth watching for patient investors, but current lack of definitive data poses ...

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...

The long, strange trip to turn psychedelic drugs into approved medicines has hit a bad batch of developments in recent months ...